Nivolumab and Ipilimumab +/-UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)

被引：0
|
作者：
Haakensen, V. [1 ]
Nowak, A. [2 ]
Ellingsen, E. [3 ]
Grundberg, O. [4 ]
Farooqi, S. [1 ]
Mcculloch, T. [5 ]
Cedres, S. [6 ]
Bjaanaes, M. [1 ]
Helland, A. [7 ,8 ]
机构：
[1] Oslo Univ Hosp, Div Canc Med, Oslo, Norway
[2] Univ Western Australia, Natl Ctr Asbestos Related Dis, Crawley, ACT, Australia
[3] Ultimovacs Asa, Oslo, Norway
[4] Karolinska Inst, Stockholm, Sweden
[5] Aalborg Univ Hosp, Aalborg, Denmark
[6] Vall Dhebron Inst Oncol Vhio, Med Oncol, Vall Dhebron Barcelona Hosp Campus, Barcelona, Spain
[7] Univ Oslo, Clin Med, Oslo, Norway
[8] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Immunotherapy; Mesothelioma; clinical trial;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P24.07
引用
收藏
页码：S380 / S380
页数：1
相关论文
共 50 条
  • [21] First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743
    Scherpereel, Arnaud
    Antonia, Scott
    Bautista, Yolanda
    Grossi, Francesco
    Kowalski, Dariusz
    Zalcman, Gerard
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Sun, Xiaowu
    Lawrance, Rachael
    Zhang, Xiaoqing
    Daumont, Melinda J.
    Bennett, Bryan
    McKenna, Mike
    Baas, Paul
    LUNG CANCER, 2022, 167 : 8 - 16
  • [22] Feasibility of a 2nd cycle of catumaxomab treatment in patients with malignant ascites: results of the SECIMAS study
    Oskay-Oezcelik, G.
    Vergote, I
    Santoro, A.
    Marme, F.
    Rosenberg, P.
    Sehouli, J.
    ONKOLOGIE, 2012, 35 : 62 - 62
  • [23] First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
    Peters, S.
    Scherpereel, A.
    Cornelissen, R.
    Oulkhouir, Y.
    Greillier, L.
    Kaplan, M. A.
    Talbot, T.
    Monnet, I
    Hiret, S.
    Baas, P.
    Nowak, A. K.
    Fujimoto, N.
    Tsao, A. S.
    Mansfield, A. S.
    Popat, S.
    Zhang, X.
    Hu, N.
    Balli, D.
    Spires, T.
    Zalcman, G.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 488 - 499
  • [24] A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update
    Ellingsen, Espen Basmo
    Aamdal, Elin
    Inderberg, Else Marit
    Rasch, Wenche
    Brunsvig, Paal
    Aamdal, Steinar
    Hovig, Eivind
    Nyakas, Marta
    Guren, Tormod Kyrre
    Gaudernack, Gustav
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [25] A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
    Meindl-Beinker, Nadja M.
    Betge, Johannes
    Gutting, Tobias
    Burgermeister, Elke
    Belle, Sebastian
    Zhan, Tianzuo
    Schulte, Nadine
    Maenz, Martin
    Ebert, Matthias P.
    Haertel, Nicolai
    BMC CANCER, 2019, 19 (1)
  • [26] A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)
    Nadja M. Meindl-Beinker
    Johannes Betge
    Tobias Gutting
    Elke Burgermeister
    Sebastian Belle
    Tianzuo Zhan
    Nadine Schulte
    Martin Maenz
    Matthias P. Ebert
    Nicolai Haertel
    BMC Cancer, 19
  • [27] Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series
    Shimamoto, Takayuki
    Morimoto, Yoshie
    Nitta, Naohiro
    Yoshida, Rie
    Tani, Nozomi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [28] 2ND MALIGNANT-TUMORS IN PATIENTS WITH LARYNGEAL CARCINOMA - DIAGNOSIS, TREATMENT, AND PREVENTION
    MCDONALD, S
    HAIE, C
    RUBIN, P
    NELSON, D
    DIVERS, LD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 17 (03): : 457 - 465
  • [29] Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
    Scherpereel, Arnaud
    Mazieres, Julien
    Greillier, Laurent
    Lantuejoul, Sylvie
    Do, Pascal
    Bylicki, Olivier
    Monnet, Isabelle
    Corre, Romain
    Audigier-Valette, Clarisse
    Locatelli-Sanchez, Myriam
    Molinier, Olivier
    Guisier, Florian
    Urban, Thierry
    Ligeza-Poisson, Catherine
    Planchard, David
    Amour, Elodie
    Morin, Franck
    Moro-Sibilot, Denis
    Zalcman, Gerard
    LANCET ONCOLOGY, 2019, 20 (02): : 239 - 253
  • [30] Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first- line treatment of advanced soft tissue sarcoma (STS).
    Gordon, Erlinda Maria
    Chua-Alcala, Victoria S.
    Kim, Katherine
    Tseng, William W.
    Quon, Doris M.
    Chawla, Sant P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
12345